Your browser doesn't support javascript.
loading
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Shi, Y K; Wang, L; Han, B H; Li, W; Yu, P; Liu, Y P; Ding, C M; Song, X; Ma, Z Y; Ren, X L; Feng, J F; Zhang, H L; Chen, G Y; Han, X H; Wu, N; Yao, C; Song, Y; Zhang, S C; Song, W; Liu, X Q; Zhao, S J; Lin, Y C; Ye, X Q; Li, K; Shu, Y Q; Ding, L M; Tan, F L; Sun, Y.
Afiliação
  • Shi YK; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Electronic address: syuankai@cicams.ac.cn.
  • Wang L; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
  • Han BH; Department of Pulmonology, Shanghai Chest Hospital, Shanghai.
  • Li W; Department of Oncology, The First Hospital Affiliated to Jilin University, Changchun.
  • Yu P; Department of Lung Cancer Medical Oncology, Sichuan Cancer Hospital, Chengdu.
  • Liu YP; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang.
  • Ding CM; Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang.
  • Song X; Department of Respiratory Medicine, Shanxi Provincial Tumor Hospital, Taiyuan.
  • Ma ZY; Department of Oncology, Henan Cancer Hospital, Zhengzhou.
  • Ren XL; Department of Respiratory Medicine, Xijing Hospital, The Fourth Military Medical University, Xi'an.
  • Feng JF; Department of Oncology, Jiangsu Cancer Hospital, Nanjing.
  • Zhang HL; Department of Oncology, Tangdu Hospital, The Fourth Military Medical University, Xi'an.
  • Chen GY; Department of Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin.
  • Han XH; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
  • Wu N; Department of Imaging Diagnosis, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
  • Yao C; Department of Biostatistics, Peking University Clinical Research Institute, Beijing.
  • Song Y; Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing.
  • Zhang SC; Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing.
  • Song W; Department of Radiology, Peking Union Medical College Hospital, Beijing.
  • Liu XQ; Department of Pulmonary Oncology, The 307th Hospital of Chinese People's Liberation Army, Beijing.
  • Zhao SJ; Department of Imaging Diagnosis, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
  • Lin YC; Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou.
  • Ye XQ; Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang.
  • Li K; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin.
  • Shu YQ; Department of Oncology, Jiangsu Provincial Hospital, Nanjing.
  • Ding LM; Betta Pharmaceuticals Co., Ltd, Hangzhou, China.
  • Tan FL; Betta Pharmaceuticals Co., Ltd, Hangzhou, China.
  • Sun Y; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Ann Oncol ; 28(10): 2443-2450, 2017 Oct 01.
Article em En | MEDLINE | ID: mdl-28945850
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinazolinas / Protocolos de Quimioterapia Combinada Antineoplásica / Éteres de Coroa / Receptores ErbB / Neoplasias Pulmonares Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinazolinas / Protocolos de Quimioterapia Combinada Antineoplásica / Éteres de Coroa / Receptores ErbB / Neoplasias Pulmonares Idioma: En Ano de publicação: 2017 Tipo de documento: Article